EUCTR2005-003050-96-IT进行中（未招募）不适用
Multicentre, prospective, assessor-blind, in parallel groups randomised and vs reference marketed product controlled confirmatory trial of the efficacy and safety of IBSA BMV medicated plaster for the treatment of chronic plaque psoriasis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- IBSA
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Comparison of efficacy and safety of Betesil® medicated plaster versus Daivobet®/Dovobet® ointment in the treatment of chronic plaque psoriasisChronic plaque psoriasisSkin and Connective Tissue DiseasesPsoriasisISRCTN34974208Institut Biochimique SA (IBSA) (Switzerland)300
已完成
3 期
Efficacy and safety of Institut Biochimique SA (IBSA) 0.1% betamethasone valerate (BMV) medicated plaster versus reference marketed product for the treatment of chronic plaque psoriasisISRCTN68864186Institut Biochimique SA (IBSA) (Switzerland)180
进行中（未招募）
不适用
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet/Dovobet, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis. - NDEUCTR2009-016969-28-ITIBSA INSTITUT BIOCHIMIQUE SA300
进行中（未招募）
1 期
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50µg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.EUCTR2009-016969-28-FRIBSA, Institut Biochimique SA
已完成
3 期
A Phase III clinical trial of Teriparatide in postmenopausal women with osteoporosisCTRI/2021/04/032769Intas Pharmaceuticals Ltd